Analysts at StockNews.com assumed coverage on shares of Conformis (NASDAQ:CFMS – Get Rating) in a research note issued to investors on Monday. The brokerage set a “hold” rating on the medical instruments supplier’s stock.
CFMS has been the topic of several other reports. Oppenheimer lifted their price target on shares of Conformis from $1.25 to $8.00 and gave the company an “outperform” rating in a report on Friday, November 11th. Canaccord Genuity Group decreased their price target on shares of Conformis from $2.00 to $1.00 and set a “buy” rating on the stock in a report on Thursday, August 11th.
Conformis Price Performance
Shares of NASDAQ:CFMS opened at $2.03 on Monday. The stock has a market capitalization of $15.26 million, a PE ratio of -0.23 and a beta of 1.14. The company has a current ratio of 5.07, a quick ratio of 4.04 and a debt-to-equity ratio of 0.33. The firm has a 50 day moving average of $0.36 and a 200-day moving average of $0.34. Conformis has a 12 month low of $1.20 and a 12 month high of $25.50.
Institutional Investors Weigh In On Conformis
A number of institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp grew its holdings in Conformis by 2.3% during the 3rd quarter. Bank of New York Mellon Corp now owns 368,020 shares of the medical instruments supplier’s stock worth $71,000 after acquiring an additional 8,191 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of Conformis by 4.1% in the 3rd quarter. Renaissance Technologies LLC now owns 4,763,691 shares of the medical instruments supplier’s stock worth $911,000 after purchasing an additional 188,200 shares during the period. MYDA Advisors LLC acquired a new position in shares of Conformis in the 3rd quarter worth approximately $133,000. Jane Street Group LLC acquired a new position in shares of Conformis in the 2nd quarter worth approximately $84,000. Finally, Millennium Management LLC acquired a new position in shares of Conformis in the 2nd quarter worth approximately $160,000. 43.72% of the stock is owned by institutional investors.
Conformis Company Profile
Conformis, Inc, a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, a custom-made partial knee replacement option for either unicompartmental or bicompartmental osteoarthritis of the knee; iTotal CR, a cruciate retaining total knee replacement product; iTotal PS, a posterior stabilized knee replacement product, as well as provides iTotal Identity and Identity Imprint knee replacement products.
- Get a free copy of the StockNews.com research report on Conformis (CFMS)
- Here’s Why SoFi Technologies Stock is Cheap at These Levels
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
Receive News & Ratings for Conformis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conformis and related companies with MarketBeat.com's FREE daily email newsletter.